CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 19 enrolled
Drug / intervention
PARO therapy sealdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05075395
NCT05075395N/ACompleted
CompareCT.gov

Animal Assisted Interactions With an Animal Robot During Physical and Occupational Therapy Sessions in the Pediatric ICU: A Feasibility Study

University of Nebraska·interventional·Posted Oct 12, 2021·Updated Dec 16, 2024

In Brief

A clinical study evaluating PARO therapy seal for Acute Lymphoblastic Leukemia (ALL) and 4 related conditions. Completed, enrolled 19 participants across 1 site.

Detailed Summary

The purpose of this study is to: 1. Establish the feasibility and acceptability of a therapeutic robot, Paro, for critically ill patients admitted to the Pediatric Intensive Care Unit 2. Explore safety considerations related to infection control \[participant hospital-acquired infection (HAI) rates, screening for the presence of microbial contamination with real-time adenosine triphosphate (ATP) testing 3. Examine the therapeutic effect of Paro on patient psychological variables, physiological variables, and sedative and analgesic medication requirements.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Lymphoblastic Leukemia (ALL), Critical Illness, Physical Therapy Modalities, Occupational Therapy, Animal Assisted Therapy
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedOct 12, 2021
Enrollment StartJul 1, 2019
Primary CompletionJun 30, 2022
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 4.7 years ago

Interventions

PARO therapy sealdevice

PARO, a baby harp seal, is an advanced interactive, therapeutic medical robot developed by AIST, a leading Japanese industrial automation pioneer. It allows the documented benefits of animal therapy to be administered to patients in environments such as hospitals and extended care facilities where live animals present treatment or logistical difficulties.